VTGN Q1 2026 Earnings Narrowing Losses as Pipeline Progress Steadies Investor Sentiment VLTO Q1 2026 Earnings EPS Beat of 435 Fails to Lift Shares as Revenue Details Remain Unclear Marker Therapeutics Q1 2026 Earnings NarrowerthanExpected Loss as Clinical Pipeline Progresses Vaxcyte PCVX Q1 2026 Earnings WiderthanExpected Loss as PreRevenue Biotech Advances Pipeline TEO Q1 2026 Earnings Massive EPS Surprise But Modest Market Reaction MSCI Inc MSCI Q1 2026 Earnings Narrow EPS Beat Reflects Stability in Index Analytics